Form D · Biotechnology
Marker Therapeutics, Inc.
Houston, TX · CIK 0001094038
Offering snapshot reported Dec 30, 2024 · SEC filing
- Reported sold
- $16.1M Offering amount: $16.1M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Dec 23, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 30, 2024 | Initial | $16,100,000 | No comparison | 5 | SEC filing |
| May 24, 2018 | Initial | $3,100,000 | No comparison | 1 | SEC filing |
| Jun 29, 2017 | Initial | $6,190,002 | No comparison | 87 | SEC filing |
| Sep 9, 2016 | Amendment | $3,135,195 | $709,000vs Aug 23, 2016 | 46 | SEC filing |
| Aug 25, 2016 | Initial | $0 | No comparison | 11 | SEC filing |
| Aug 23, 2016 | Initial | $2,426,195 | No comparison | 29 | SEC filing |
| Jun 2, 2010 | Initial | $1,275,000 | No comparison | 4 | SEC filing |
| Nov 10, 2009 | Initial | $350,000 | No comparison | 1 | SEC filing |
| Nov 10, 2009 | Initial | $135,000 | No comparison | 10 | SEC filing |
| Nov 10, 2009 | Initial | $700,000 | No comparison | 3 | SEC filing |
| Aug 14, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 26, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 15, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $816K
- Finders' fees
- $0
- Form D file number
- 021-533696
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| CANACCORD GENUITY LLC | 000001020 | |
| Brookline Capital Markets, a division of Arcadia Securities, LLC | 000044656 |
Source: Form D, filed Dec 30, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Bonfiglio | Director, Executive |
| Denis Corin | Director, Executive |
| David Eansor | Director |
| Steven Elms | Director |
| Sherry Grisewood | Director |
| Peter Hoang | Director, Executive |
| Katharine Knobil | Director |
| David Laskow Pooley | Director |
| Michael Loiacono | Executive |
| Tracy Moore | Director, Executive |
| Mark Reddish | Director |
| Joshua Silverman | Director |
| Juan Vera | Director, Executive |
| Frederick Wasserman | Director |
| John Wilson | Director |
| Glynn Wilson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2450 Holcombe Blvd Suite Bcm A, Ms: Bcm251
Houston, TX, 77021
Houston, TX, 77021